Evaluating the Efficacy of Autologous Mesenchymal Stem Cell Therapy in Improving Endometrial Receptivity and Implantation Success in IVF Patients
- Jul 18
- 2 min read
Updated: 3 days ago
DOI 10.66715/jsccr/2026.v3.i3.5462 | Original Research | 2026 | Volume - 3 | Issue - 3 | Page 54-62
1) Prof. Dr. V. Balasubramanian, Dean, Principal, School of Pharmacy, Joy University, Tirunelveli, Tamil Nadu.
2) Dr. Prof. A. Kumar, Associate Professor, Department of Anatomy, JHMCRI, WB
3) Dr. Manoj Kumar, Tutor, Department of Physiology, JHMC, Web
Abstract
Background: Thin endometrium and impaired endometrial receptivity remain significant challenges in assisted reproductive technology (ART), contributing to repeated implantation failure (RIF) and reduced pregnancy rates despite advances in in vitro fertilization (IVF). Autologous mesenchymal stem cell (MSC) therapy has emerged as a promising regenerative strategy owing to its immunomodulatory, angiogenic, and tissue-repair properties.
Objective: This study aimed to evaluate the efficacy of autologous mesenchymal stem cell therapy in improving endometrial receptivity and implantation success among women undergoing IVF treatment.
Methods: A prospective controlled clinical study was conducted involving 100 women with thin endometrium or recurrent implantation failure undergoing IVF. Participants were allocated into two groups: the MSC group (n = 50), which received intrauterine administration of autologous bone marrow- or adipose tissue-derived mesenchymal stem cells before embryo transfer, and the control group (n = 50), which received conventional endometrial preparation alone. Primary outcomes included endometrial thickness, vascularity, implantation rate, clinical pregnancy rate, and ongoing pregnancy rate. Secondary outcomes included changes in endometrial receptivity markers and treatment-related adverse events.
Results: Patients receiving autologous MSC therapy demonstrated a significant increase in endometrial thickness (from 5.8 ± 0.7 mm to 8.6 ± 0.9 mm; p < 0.001) and improved sub-endometrial vascularity compared with controls. Implantation rates were significantly higher in the MSC group (42%) than in the control group (26%) (p = 0.02). Clinical pregnancy (52% vs. 34%) and ongoing pregnancy rates (46% vs. 30%) also showed significant improvement following MSC therapy. No serious treatment-related adverse events were observed.
Conclusion: Autologous mesenchymal stem cell therapy significantly enhances endometrial regeneration, receptivity, and implantation outcomes in women undergoing IVF. The findings suggest that MSC-based regenerative treatment represents a safe and effective adjunctive strategy for patients with thin endometria or recurrent implantation failure. However, larger multicenter randomised controlled trials with long-term follow-up are warranted to confirm its clinical efficacy and optimise treatment protocols.